Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05050149 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
A Phase 2 study, sponsored by Palvella Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT05050149 is a Phase 2 study that has completed, run by Palvella Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT05050149, a Phase 2 study, has completed, sponsored by Palvella Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months of PTX-022 treatment by the end of the study.
Interventions
- DRUG PTX-022
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-01-13 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05050149
The ClinicalTrials.gov registry entry for NCT05050149 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Palvella Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PTX-022 is the first listed.
NCT05050149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05050149 about?
NCT05050149 is a clinical study titled "Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations". This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months of PTX-022 treatment by the end of the study.
What is the current status of trial NCT05050149?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2022-01-13. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT05050149?
The interventions under investigation include: PTX-022 (DRUG).
Who is sponsoring clinical trial NCT05050149?
This trial is sponsored by Palvella Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.